| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects (NCT05976737) | The Affiliated Hospital of Qingdao University | 2023-08-17 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1558 in Healthy Adult Volunteers (NCT06010589) | Daewoong Pharmaceutical Co. LTD. | 2023-08-17 |
| Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience (NCT06072170) | Altasciences Company Inc. | 2023-08-16 |
| A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (NCT05944978) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-08-16 |
| A Study of BA1202 in Patients With Advanced Solid Tumors (NCT05909241) | Shandong Boan Biotechnology Co., Ltd | 2023-08-16 |
| A Study of QLF3108 in Participants With Advanced Solid Tumor (NCT06019013) | Qilu Pharmaceutical Co., Ltd. | 2023-08-16 |
| Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects (NCT05523401) | University Hospital, Basel, Switzerland | 2023-08-16 |
| Measurement of Insulin Levels in Cerebral Spinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose (NCT05866367) | HealthPartners Institute | 2023-08-16 |
| A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (NCT06006273) | M.D. Anderson Cancer Center | 2023-08-16 |
| NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (NTCDU) (NCT06020664) | NOxy Health Products, LLC | 2023-08-16 |
| A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor (NCT05997342) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-16 |
| Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC (NCT05272865) | LaSanta S A S | 2023-08-15 |
| A Phase I Study of XJ101 in Chinese Healthy Subjects (NCT06014736) | Starmab biologics（Shanghai）Co,.ltd | 2023-08-15 |
| CAR T Cells to Target GD2 for DMG (NCT05544526) | University College, London | 2023-08-15 |
| A Study of Imvotamab in Severe Systemic Lupus Erythematosus (NCT06041568) | IGM Biosciences, Inc. | 2023-08-15 |
| A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age (NCT05995275) | ModernaTX, Inc. | 2023-08-15 |
| PXL-Platinum 330 in Eyes With Corneal Thinning Conditions (NCT05489510) | Vishal Jhanji | 2023-08-15 |
| A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer (NCT06011291) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-08-15 |
| A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. (NCT05877924) | NovaRock Biotherapeutics, Ltd | 2023-08-15 |
| A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). (NCT05975645) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-15 |
| mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT05918250) | ModernaTX, Inc. | 2023-08-15 |
| Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma (NCT05949944) | Sun Yat-sen University | 2023-08-15 |
| Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations (NCT05820152) | Neurophth Therapeutics Inc | 2023-08-15 |
| A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants (NCT05965219) | Cerevel Therapeutics, LLC | 2023-08-15 |
| Gene Therapy(FT-003) for Wet AMD (NCT06492863) | Frontera Therapeutics | 2023-08-15 |
| CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study (NCT06136364) | Hebei Senlang Biotechnology Inc., Ltd. | 2023-08-15 |
| Targeting Endoplasmic Reticulum Stress in Human Hypertension (NCT06025630) | University of North Texas Health Science Center | 2023-08-15 |
| Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma (NCT05983237) | Jun Guo | 2023-08-15 |
| Effect of Pharmacokinetics in Healthy Chinese Subjects (NCT06005714) | Shanghai Vinnerna Biosciences Co., Ltd. | 2023-08-15 |
| A Study of DCR-STAT3 in Adults With Solid Tumors (NCT06098651) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2023-08-14 |
| Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers. (NCT05930782) | Medicines for Malaria Venture | 2023-08-14 |
| A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE) (NCT06783192) | Merck Sharp & Dohme LLC | 2023-08-14 |
| Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults (NCT05891236) | Gates Medical Research Institute | 2023-08-14 |
| A Study of EDG-7500 in Healthy Adults (NCT06011317) | Edgewise Therapeutics, Inc. | 2023-08-14 |
| A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease (NCT05970640) | Boehringer Ingelheim | 2023-08-14 |
| Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease (NCT05667649) | Regeneration Biomedical, Inc. | 2023-08-14 |
| A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants (NCT05996874) | Novo Nordisk A/S | 2023-08-12 |
| A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults (NCT05995249) | Takeda | 2023-08-11 |
| Single Dose IV Methadone for Post-Op Pain (NCT05425420) | Kanecia Obie Zimmerman | 2023-08-11 |
| A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis. (NCT06673654) | Sun Pharmaceutical Industries, Inc. | 2023-08-11 |
| A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors (NCT06043466) | Chongqing Precision Biotech Co., Ltd | 2023-08-11 |
| A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors (NCT06209385) | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2023-08-11 |
| Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas (NCT05965505) | Axter Therapeutics (Beijing) Co., Ltd | 2023-08-11 |
| NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma (NCT06012695) | Novelwise Pharmaceutical Corporation | 2023-08-11 |
| A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. (NCT06015048) | Jiangsu HengRui Medicine Co., Ltd. | 2023-08-11 |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (NCT05927571) | Genentech, Inc. | 2023-08-10 |
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors (NCT05407441) | Susan Chi, MD | 2023-08-10 |
| Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC (NCT05768347) | H. Lee Moffitt Cancer Center and Research Institute | 2023-08-10 |
| The MAD Study of SSGJ-613 in Healthy Subjects (NCT05966701) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2023-08-10 |
| A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese Participants (NCT07154095) | West China Second University Hospital | 2023-08-10 |
| A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the Body (NCT05879991) | Boehringer Ingelheim | 2023-08-10 |
| Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 (NCT05980416) | Elevation Oncology | 2023-08-10 |
| Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer (NCT05997615) | Vir Biotechnology, Inc. | 2023-08-10 |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors (NCT05372640) | National Cancer Institute (NCI) | 2023-08-10 |
| Mechanisms of Diuretic Resistance in Heart Failure, Aim 2 (NCT05753059) | Yale University | 2023-08-10 |
| Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer (NCT05978401) | Guangzhou Gloria Biosciences Co., Ltd. | 2023-08-10 |
| A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation (NCT06006793) | Shouyao Holdings (Beijing) Co. LTD | 2023-08-10 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects (NCT06014853) | Bukwang Pharmaceutical | 2023-08-10 |
| A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) (NCT05939596) | AIM Vaccine Co., Ltd. | 2023-08-10 |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma (NCT05861050) | City of Hope Medical Center | 2023-08-10 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy Volunteers (NCT06008028) | Boryung Pharmaceutical Co., Ltd | 2023-08-10 |
| Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM (NCT05836259) | Tenaya Therapeutics | 2023-08-10 |
| Safety of Extracellular Vesicles for Burn Wounds (NCT05078385) | Aegle Therapeutics | 2023-08-10 |
| A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours (NCT06237413) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2023-08-10 |
| A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD) (NCT06007651) | Eli Lilly and Company | 2023-08-10 |
| A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults (NCT05907395) | Pfizer | 2023-08-09 |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (NCT05617885) | Praful Ravi, MB BCHir, MRCP | 2023-08-09 |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors (NCT05958121) | Immatics Biotechnologies GmbH | 2023-08-09 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) (NCT05984784) | Inmagene LLC | 2023-08-09 |
| The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. (NCT05774873) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-08-09 |
| A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors (NCT05509985) | AskGene Pharma, Inc. | 2023-08-09 |
| Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults (NCT05968989) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-08-09 |
| A Study of LY3871801 in Healthy Asian and Non-Asian Participants (NCT05960851) | Eli Lilly and Company | 2023-08-09 |
| Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants (NCT05937386) | Agomab Spain S.L. | 2023-08-09 |
| To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis (NCT06296095) | Anhui Provincial Hospital | 2023-08-09 |
| A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection (NCT05584683) | Kaizen Bioscience Co. | 2023-08-09 |
| A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (NCT05553132) | Daniel B. F. Saris | 2023-08-08 |
| A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years (NCT05989672) | GlaxoSmithKline | 2023-08-08 |
| A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants (NCT05963932) | Bristol-Myers Squibb | 2023-08-08 |
| NVG-291 in Spinal Cord Injury Subjects (NCT05965700) | NervGen Pharma | 2023-08-08 |
| Study of ZG0895.HCl in Patients With Advanced Solid Tumors (NCT05877664) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2023-08-08 |
| Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers (NCT05981768) | Achieve Life Sciences | 2023-08-08 |
| Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures. (NCT05987033) | Novadip Biosciences | 2023-08-08 |
| A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma (NCT06006286) | M.D. Anderson Cancer Center | 2023-08-08 |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors (NCT05983432) | SystImmune Inc. | 2023-08-08 |
| A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy (NCT05798026) | Eutilex | 2023-08-08 |
| Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma (NCT06310590) | Chengdu New Radiomedicine Technology Co. LTD. | 2023-08-08 |
| A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants (NCT05994807) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2023-08-08 |
| Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (NCT05876312) | ADARx Pharmaceuticals, Inc. | 2023-08-07 |
| Azithromycin Before Induction (NCT06543290) | Arrowhead Regional Medical Center | 2023-08-07 |
| Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) (NCT05840510) | Mirati Therapeutics Inc. | 2023-08-07 |
| A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants (NCT05970718) | Regeneron Pharmaceuticals | 2023-08-07 |
| ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer (NCT05824559) | MEI Pharma, Inc. | 2023-08-07 |
| A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (NCT05858164) | Bayer | 2023-08-07 |
| A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies (NCT06049667) | Nanjing Chia-tai Tianqing Pharmaceutical | 2023-08-07 |
| Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies (NCT06037018) | CytoCares Inc | 2023-08-07 |
| Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects (NCT05954169) | Jiangsu HengRui Medicine Co., Ltd. | 2023-08-07 |
| A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria (NCT05972629) | Sanofi | 2023-08-07 |
| Neonatal Phase 1 Valacyclovir Study (NCT05468619) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-08-07 |
| A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. (NCT05970016) | Beijing Tide Pharmaceutical Co., Ltd | 2023-08-07 |